Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | What is the focus of lymphoma research in 2017?

Anas Younes • 29 Mar 2017
BSH 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Hodgkin Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma

Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses future directions of lymphoma research at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about ongoing research into biomarkers and precision medicine, highlighting that all lymphoma patients who give consent are being sequenced at the Memorial Sloan Kettering Cancer Center. Prof. Younes also discusses the potential of doublet or triplet combination therapies, as well as different types of immunotherapy.

More from Anas Younes

Fimepinostat with venetoclax in R/R lymphoma
1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
Atezolizumab plus R-CHOP in DLBCL: encouraging results
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals